Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.
- BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.
- Details of the presentation are as follows:
Title: Role of Plasma Inorganic Pyrophosphate in Calciphylaxis: A Prospective Study
Calciphylaxis is a rare disorder with a high mortality rate that mostly affects patients with end stage kidney disease (ESKD). - The estimated incidence of calciphylaxis is at least 1,800 new patients per year in the United States and there are no approved therapies.
- Inozyme previously presented data at the European Calcified Tissue Society Congress (ECTS) which showed that morbidity and mortality in patients with calciphylaxis were associated with low levels of PPi.